Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
Helen Ruth StaggGraham H BothamleyJennifer A DavidsonHeinke KunstMaeve K LalorMarc C LipmanMiranda G LoutetStefan LozewiczTehreem MohiyuddinAula AbbaraEliza AlexanderHelen BoothDean D CreerRoss J HarrisOnn Min KonMichael R LoebingerTimothy D McHughHeather J MilburnParamita PalchaudhuriPatrick Peter John PhillipsErik SchmokLucy TaylorIbrahim Abubakarnull nullPublished in: The European respiratory journal (2019)
In a high-income setting, we found a 12-month (H)RfZE regimen with a short Z duration to be similarly effective for Hr tuberculosis with or without a Fq. This regimen may result in fewer adverse events than the WHO recommendations.